AMINOCAPROIC ACID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aminocaproic Acid, and when can generic versions of Aminocaproic Acid launch?
Aminocaproic Acid is a drug marketed by Abraxis Pharm, Baxter Hlthcare, Hospira, Luitpold, Amneal, Annora Pharma, Aurobindo Pharma, Belcher, Carnegie, Epic Pharma Llc, Florida, Sunny, Taro, Tulex Pharms Inc, Vistapharm, Ani Pharms, Edenbridge Pharms, MSN, and Optimus. and is included in twenty-three NDAs.
The generic ingredient in AMINOCAPROIC ACID is aminocaproic acid. There are six drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the aminocaproic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aminocaproic Acid
A generic version of AMINOCAPROIC ACID was approved as aminocaproic acid by LUITPOLD on December 1st, 1987.
Summary for AMINOCAPROIC ACID
US Patents: | 0 |
Applicants: | 19 |
NDAs: | 23 |
Finished Product Suppliers / Packagers: | 18 |
Raw Ingredient (Bulk) Api Vendors: | 183 |
Clinical Trials: | 37 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for AMINOCAPROIC ACID |
What excipients (inactive ingredients) are in AMINOCAPROIC ACID? | AMINOCAPROIC ACID excipients list |
DailyMed Link: | AMINOCAPROIC ACID at DailyMed |
Recent Clinical Trials for AMINOCAPROIC ACID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Minia University | Phase 3 |
NYU Langone Health | N/A |
Assiut University | Phase 4 |
Pharmacology for AMINOCAPROIC ACID
Drug Class | Antifibrinolytic Agent |
Physiological Effect | Decreased Fibrinolysis |